Three years of growth hormone therapy in children born small for gestational age: results from the ANSWER Program
Growth hormone (GH) is used to treat short stature and growth failure associated with growth disorders. Birth size and GH status variably modulate response to GH therapy. The aim of this study was to determine the effect of birth size on response to GH therapy, and to determine the impact of GH status in patients born small for gestational age (SGA) on response to GH therapy. Data from the prospective, non-interventional American Norditropin® Studies: Web-Enabled Research (ANSWER) Program were analyzed for several growth outcomes in response to GH therapy over 3 years. GH-naïve children from the ANSWER Program were included in this analysis: SGA with peak GH ≥10 ng/mL (20 mIU/l), SGA with peak GH/mL (20 mIU/l), isolated growth hormone deficiency (IGHD) born SGA, IGHD not born SGA, and idiopathic short stature. For patients with IGHD, those who did not meet criteria for SGA at birth showed greater improvements in height SDS and BMI SDS than patients with IGHD who met criteria for SGA at birth. For patients born SGA, response to GH therapy varied with GH status. Therefore, unlike previous guidelines, we recommend that GH status be established in patients born SGA to optimize GH therapy.
Rapaport, Robert; Lee, Peter; Ross, Judith L.; Saenger, Paul; Ostrow, Vlady; and Piccoli, Giuseppe, "Three years of growth hormone therapy in children born small for gestational age: results from the ANSWER Program" (2018). Department of Pediatrics Faculty Papers. Paper 84.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
This article has been peer reviewed. It is the author’s final published version in Endocrine Connections, Volume 7, Issue 10, October 2018, Pages 1096-1104.
The published version is available at https://doi.org/10.1530/EC-18-0286. Copyright © Rapaport et al.